Pharma
Deals

Why Sun Pharma is shelling out USD576 million on a hair-loss drug to fire its specialty-drugs game

Why Sun Pharma is shelling out USD576 million on a hair-loss drug to fire its specialty-drugs game
Getty Images

Sun Pharmaceutical Industries Ltd. corporate office in the Andheri suburb of Mumbai

Synopsis

Sun Pharma’s biggest acquisition in specialty drugs gives the company rights to the lead candidate deuruxolitinib, a drug said to be a “potential best-in-class” treatment for alopecia areata, an autoimmune disorder that leads to hair loss. What are the factors that prompted Sun Pharma to go for this big bet?

By &
9 mins read, Last Updated:
Sun Pharmaceutical Industries is scaling new heights. After a setback in the US generic-drugs business, India’s largest drugmaker has gradually moved up the value chain and built a sizeable specialty-drugs business over the last few years. Dilip Shanghvi, founder and managing director of Sun Pharma, with his astute sense of business and passion for science, has dodged critics and patiently created a specialty-drugs portfolio through a string of
( Originally published on Jan 23, 2023 )

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion

Subscribe Now

Monsoon Offer

Get flat 20% off

on ETPrime membership

Membership Benefits

Access the exclusive Economic Times

Stories, Editorial & Expert opinion

Complete Access with ET Prime

Experience your Economic Times newspaper, The way you've always liked!

Get to know where the market gurus invest & grow your portfolio.

Stock Report Plus

In-depth stock analysis for 4000+ companies

Stock Analyzer

Instant stock analysis based on Solvency, Profitability, Growth, Valuation, Momentum, Risk & More.

Now Available with ET Prime

Manage your money efficiently with this weekly guide.

Clean experience

with minimal ads

Easy & distraction-free reading with 90% less ads

Sharp Insight-rich,

In-depth stories across 20+ sectors

1500+ Exclusive stories & analysis across sectors to help you stay informed

Get One Year Times Prime Subscription worth ₹1199 for free

Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-

Enjoy unlimited access to breaking news and thought provoking stories from all around the world.

Get One Year Docubay Subscription worth ₹999 for free

Stream award-winning international documentaries from more than 100 countries.

Offers By Our Partners

Exclusively for ET Prime Members

Members Love Us

The stalwarts of the industry trust ET Prime for insightful analysis & unbiased thought pieces

Gift a story

Your membership includes Story Gifting Credits. Now gift exclusive stories to your friends & peers.

Comment & Engage

with ET Prime community

Communicate & build a connection with great minds of the industry

A trusted team of

Journalists & Analysts

Unbiased perspective & detailed reporting by our team of journalists who have in-depth knowledge and years of experience